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Background: Neuroblastoma (NB) is the most common extracranial solid tumor in children. NB tumors and derived
cell lines are phenotypically heterogeneous. Cell lines are classified by phenotype, each having distinct
differentiation and tumorigenic properties. The neuroblastic phenotype is tumorigenic, has neuronal features and
includes stem cells (I-cells) and neuronal cells (N-cells). The non-neuronal phenotype (S-cell) comprises cells that are
non-tumorigenic with features of glial/smooth muscle precursor cells. This study identified miRNAs associated with
each distinct cell phenotypes and investigated their role in regulating associated differentiation and tumorigenic
properties.
Methods: A miRNA microarray was performed on the three cell phenotypes and expression verified by qRT-PCR.
miRNAs specific for certain cell phenotypes were modulated using miRNA inhibitors or stable transfection. Neuronal
differentiation was induced by RA; non-neuronal differentiation by BrdU. Changes in tumorigenicity were assayed by
soft agar colony forming ability. N-myc binding to miR-375 promoter was assayed by chromatin-immunoprecipitation.
Results: Unsupervised hierarchical clustering of miRNA microarray data segregated neuroblastic and non-neuronal cell
lines and showed that specific miRNAs define each phenotype. qRT-PCR validation confirmed that increased levels of
miR-21, miR-221 and miR-335 are associated with the non-neuronal phenotype, whereas increased levels of miR-124
and miR-375 are exclusive to neuroblastic cells. Downregulation of miR-335 in non-neuronal cells modulates expression
levels of HAND1 and JAG1, known modulators of neuronal differentiation. Overexpression of miR-124 in stem cells
induces terminal neuronal differentiation with reduced malignancy. Expression of miR-375 is exclusive for
N-myc-expressing neuroblastic cells and is regulated by N-myc. Moreover, miR-375 downregulates expression of
the neuronal-specific RNA binding protein HuD.
Conclusions: Thus, miRNAs define distinct NB cell phenotypes. Increased levels of miR-21, miR-221 and miR-335
characterize the non-neuronal, non-malignant phenotype and miR-335 maintains the non-neuronal features possibly
by blocking neuronal differentiation. miR-124 induces terminal neuronal differentiation with reduction in malignancy.
Data suggest N-myc inhibits neuronal differentiation of neuroblastic cells possibly by upregulating miR-375 which, in
turn, suppresses HuD. As tumor differentiation state is highly predictive of patient survival, the involvement of these
miRNAs with NB differentiation and tumorigenic state could be exploited in the development of novel therapeutic
strategies for this enigmatic childhood cancer.
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NB is the most common extracranial solid tumor in chil-
dren. The outcome of patients has improved over the
years and the estimated 5-year survival rate for non-high
risk patients is 90%, whereas that for high-risk patients
is 50% [1].
Amplification of the N-myc proto-oncogene and cellu-
lar heterogeneity are two key factors that influence pa-
tient survival. The three basic cell types in NB tumors
and derived cell lines differ in their morphological, bio-
chemical and tumorigenic properties — whereas N-type
neuroblastic cells are mildly malignant and have neur-
onal characteristics, S-type cells are non-tumorigenic
with features of non-neuronal (glial, melanocytic and
smooth muscle) precursor cells. I-type cancer stem cells,
which can differentiate into either N or S cells, express
stem cell marker proteins and are highly tumorigenic
[2-4]. Thus, the three basic cell phenotypes represent
distinct differentiation states of NB with distinct tumo-
rigenic properties. All three cell types are present in tu-
mors [4]. Clinically, cellular heterogeneity is predictive
of patient outcome - patients with stroma-poor tumors
comprising undifferentiated neuroblasts are frequently
fatal whereas stroma-rich tumors or those with diffe-
rentiated ganglion cells show a better prognosis [5].
Therefore, one approach to controlling the malignant
potential of this tumor involves exploiting its unique dif-
ferentiation capacity.
MicroRNAs (miRNAs) are important regulators of gene
expression and function and hence differentiation. A role
for miRNAs in neuroblastoma has been extensively stu-
died mainly focusing on their association with respect to
N-myc amplification, chromosomal imbalances, prognosis
and retinoic acid (RA)-induced differentiation as discussed
in four reviews [6-9]. These studies have revealed that
large scale chromosomal imbalances result in dysregulated
miRNAs which have a functional role in neuroblastoma
pathogenesis and tumorigenicity. MiRNAs associated with
N-myc amplification such as miR-17-92 cluster members
are shown to be associated with NB tumorigenicity. Also,
miRNAs associated with RA-induced differentiation of
NB has been extensively studied as RA is used clinically
in treating NB patients. These studies, as reviewed by
Stalling et al., indicate that miRNA and DNA methylation
changes following RA-treatment play a critical role in
NB differentiation [9]. miRNAs modulated upon RA-
treatment are shown to regulate key genes involved in
differentiation, survival and tumorigenic properties of
NB [9].
The present study is mainly focused on investigating
the association of miRNAs with respect to the different
cell phenotypes derived from NB and their role in re-
gulating their intrinsic differentiation and tumorigenic
properties with use of large panel of NB cell lines.Methods
Cell culture and differentiation
The thirteen different human NB cell lines or clones,
established from 8 patients’ tumors or bone marrow aspi-
rates, used for these studies have been published pre-
viously (4). Seven cell lines or clones were isolated at
Memorial Sloan-Kettering Cancer Center or Fordham
University [SH-SY5Y, SH-EP1, BE(1)n, BE(2)-M17V, BE
(2)-C, SK-N-LD, and SK-N-HM], three [SMS-KCN, SMS-
LHN, and CB-JMN] were obtained from Dr. C. Patrick
Reynolds (Texas Tech University Health Sciences Center)
and SMS-KCN subsequently cloned [KCN-83n and
KCNs], and one cell line, LA-N-1, was obtained from
Dr. Robert C. Seeger (Children’s Hospital of Los Angeles)
and cloned [LA1-55n and LA1-5s]. All cell lines were
maintained in a 1:1 mixture of Eagle’s Minimum Essential
Medium with non-essential amino acids and Ham’s Nu-
trient Mixture F12 (Invitrogen Corporation, Carlsbad,
CA), supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT) without antibiotics.
miRNA microarray
miRNAs were isolated using the miRVana miRNA iso-
lation kit from Ambion (Austin, TX). Processing and ini-
tial microarray analysis of miRNA expression levels was
done by LC Sciences (Houston, TX). Levels of 313 diffe-
rent miRNAs were assayed by these arrays. Three groups
of miRNAs were deleted prior to analysis: i) miRNAs
whose expression was barely detectable in all samples
(i.e., with a mean fluorescence ≤ 100); ii) those with sta-
tistically non-significant differences (p ≥ 0.05) between
(N and I) and Mix; and iii) data from hybridizations to the
complementary strand of the miRNAs (S-hsa-miRNAs).
The expression levels of miRNAs in different groups were
analyzed by Student’s t-test.
Clustering analysis
Unsupervised clustering based on miRNA expression
profiles was generated using MultiExperiment Viewer
(MeV) version 4 (http://www.tm4.org/mev.html) using a
complete linkage-clustering algorithm with a Spearman
rank correlation metric.
Semi-quantitative RT-PCR
Semi-quantitative RT-PCR was performed using the mir-
Vana RT-PCR miRNA Detection Kit (Ambion, Austin,
TX).
qRT-PCR
cDNAs for miRNAs were synthesized using the TaqMan®
MicroRNA Reverse Transcription kit and miRNA-specific
primers and quantified using TaqMan assays (Applied
Biosystems, Foster City, CA) by comparative ΔΔCt me-
thod. Expression levels of miRNAs were normalized to U6
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standard sample of SH-SY5Y or LA1-5s.Generation of miR-124-overexpressing BE (2)-C clones
miR-124-overexpressing lentivirus was purchased from
SBI Biosciences (Mountain View, CA). BE(2)-C cells were
infected at a multiplicity of infection of 10 according to
manufacturer’s instructions and cloned using cloning
cylinders.3H-norephinephrine uptake
Cells growing in multiwell plates were incubated in triplicate
with 250 nM (1.2 μCi) 3H-norephinephrine (PerkinElmer,
Waltham, MA) for 45 min, washed 2 times, and lysed
[10]; radioactivity was measured by liquid scintillation
spectrometry and normalized to cell number.Colony forming efficiency
Colony-forming efficiencies (CFE) in soft agar were mea-
sured as described previously [4] and determined in
quadruplicate in three independent experiments.Chromatin immunoprecipitation (ChIP) assays
ChIP assays used the EZ ChIP™ Chromatin Immunopre-
cipitation Kit (Upstate Biological, Lake Placid, NY). Chro-
matin isolated from BE(2)-C cells was incubated with anti-
N-myc rabbit polyclonal antibody (sc-791) (Santa Cruz
Biotechnology, Santa Cruz, CA); mouse monoclonal anti-
RNA polymerase II antibody (clone CTD4H8) (Upstate
Biological, Lake Placid, NY); or rabbit anti-goat IgG
(Chemicon International, Temecula, CA). The primer sets
used for amplification are available upon request.Stable and transient transfections
Stable SH-SY5Y sense-N-myc and LA1-55n antisense
N-myc transfectants have been described [11]. miRNA
inhibitors for miR-375, miR-335, and control oligos
(100 nM) (Ambion, Austin, TX) were transiently trans-
fected into BE(2)-C or SH-EP1 cells for 48 hrs using Lipo-
fectamine 2000 (Invitrogen Corp., Carlsbad, CA).Western blot analysis
Western blot analysis of proteins was performed as previ-
ously described [4]. Primary antibodies used were rabbit
anti-N-myc [(C-19) (SC 791)] (Santa Cruz Biotechnology
Inc., Santa Cruz, CA), human antisera against Hu pro-
teins (a kind gift of Dr. Myrna Rosenfeld, University of
Pennsylvania Medical School) and, as controls, mouse anti-
actin [(AC-74) (076 K4762)] (Invitrogen Corp., Carlsbad,
CA) and mouse anti-Hsp72/73 [(W27) (HSP01)] (EMD
Chemicals Inc., Gibbstown, NJ).Results and discussion
miRNAs define distinct NB cell phenotypes
Levels of 313 different miRNAs from two N- and two I-
type N-myc-amplified human NB cell lines were assessed
in a miRNA microarray. These miRNA microarrays were
performed as dual assays, where each sample and the con-
trol mix was hybridized to the same chip. The control mix
included a mixture of miRNAs from these four cell lines
with those from three different S-type cells. Inclusion of
control mix enabled us to account for miRNAs that are
expressed in neuroblastoma cells regardless of phenotype.
As control mix also contains S-cell miRNAs, it also
enabled us to identify miRNAs associated with the S-type
non-tumorigenic cell phenotype by comparing it to neu-
roblastic cells (N- and I-type cells). Unsupervised hier-
archical clustering analysis of miRNA microarray data
shows that N- and I-cells cluster discretely from the S-cell
miRNA-containing control mix (Figure 1). This is con-
sistent with previous studies from our laboratory showing
N- and I-cells share many characteristics not present in
S-cells. N- and I-cells are tumorigenic and are neuroblas-
tic in terms of their morphological and biochemical cha-
racteristics, whereas S-cells are non-tumorigenic and lack
neuroblastic features [4]. Therefore, in the present study,
we use the term “neuroblastic” to collectively define
N- and I-cells and “non-neuronal” to define S-cells.
Figure 1 shows representative miRNAs that are distinctly
different between neuroblastic (N and I) cells and non-
neuronal S-cells and either highly or poorly expressed in
all NB phenotypes. MiRNAs that are distinctly different
between the neuroblastic and the non-neuronal S-cells are
of specific interest as they could regulate neuronal/non-
neuronal differentiation and/or tumorigenicity. These
were selected for further study.
To specifically identify miRNAs associated with the
non-neuronal vs neuroblastic phenotype, miRNA levels
were compared among cell lines representing these two
phenotypes. The expression levels of twenty miRNAs that
were highly significantly different between the two groups
were ranked according to fold change (Additional file 1:
Table S1). The majority of these miRNAs are highly
expressed in the S-type cell containing mix and five out of
top seven candidates that showed the highest fold change
were selected for further analysis (miR-21, miR-31, miR-
222, miR-221 and miR-335).
A second grouping compared expression levels between
the two neuroblastic phenotypes (N vs I) to identify miR-
NAs that reflect the differences in neuronal maturation
and/or malignant potential (Additional file 2: Table S2) as
N-cells show more neuronal features and are less malig-
nant than I-cells [4]. We also took into account published
studies of miRNAs associated with neuronal differen-
tiation in neuroblastoma. Three additional miRNAs, all



































































































Figure 1 Unsupervised clustering based on miRNA expression profiles was generated using MultiExperiment Viewer (MeV) version 4
(http://www.tm4.org/mev.html) and shows that N- and I-type cells are distinctly different from miRNA mix containing S-type cells.
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ther analysis.
Candidates from both analyses were validated by qRT-
PCR using a panel of 13 human NB cell lines: six N-type,
four I-type, and three S-type cell variants (Figure 2). qRT-
PCR validation of five of the selected candidates con-
firmed the microarray expression pattern. Three miRNAs,
miR-21, miR-221 and miR-335, show elevated expression
in non-neuronal S cells and are barely detectable or very
low levels in neuroblastic cells (Figure 2A, B, C). The
expression of miR-21 and miR-221 is reported to play an
oncogenic role in other types of cancers. However, their
increased expression in non-tumorigenic S-type NB cells
doesn't support a tumorigenic role for these miRNAs in
NB, they could be involved in non-neuronal differen-
tiation. Published studies of a role for the above two
miRNAs in neuroblastoma have reported that elevated
expression of miR-221 is correlated with N-myc amplifica-
tion [12]. However, our observation of its higher levels of
expression in S cells that have barely detectable levels of
N-myc protein even in the presence of amplified N-myc
gene [3] and its lower levels in neuroblastic cells those all
express N-myc protein [4] doesn’t support its upregula-
tion by N-myc. However, a study that analyzed miRNAs
in 66 primary tumors and reported that higher levels ofmiR-21 correlated with favorable outcome of the patients
supports our finding of its association with non-tumori-
genic S-type cell [13].
Expression levels of two miRNAs, miR-124 and miR-
375, were higher in the neuroblastic phenotype (Figure 2D
and E). The six N-type cell lines have the highest levels of
miR-124 expression [12.5-fold higher compared to I-type
lines] suggesting its association with neuronal differenti-
ation; S-cells have barely detectable levels of this miRNA.
The second miRNA associated with a neuroblastic lineage,
miR-375, is expressed at similar levels in both N- and
I-cells while being barely detectable in S-type cells
(Figure 2E).
Drug-induced irreversible differentiation of I-type NB
cancer stem cell confirms the association miRNAs with
cell phenotype
Treatment of I-type NB stem cells with RA causes ter-
minal neuronal differentiation whereas BrdU induces a
non-neuronal S cell phenotype [4]. To confirm the associ-
ation of the five miRNAs with cell phenotype, we analyzed
their respective expression changes in I-type BE(2)-C cells
differentiated by RA or BrdU. BrdU-induced S cell diffe-
rentiation significantly increases expression of S-type-
specific miRNAs - miR-21, miR-221 and miR-335 - by
1 2 3 4 5 6 7 8 9 10 1112 13

























































































Figure 2 qRT-PCR analysis of phenotype-specific miRNAs in NB cell lines. The cell line panel includes six N-type [SH-SY5Y (1), SMS-LHN (2),
BE(2)-M17V (3), LA1-55n (4), KCN-83n (5), SK-N-BE(1)n (6)]; four I-type [CB-JMN (7), BE(2)-C (8), SK-N-LD (9), SK-N-HM (10)]; and three S-type cell lines
[SH-EP1 (11), SMS-KCNs (12), and LA1-5s (13)]. Levels of S-cell specific (A) miR-21, (B) -221 and (C) -335 were normalized to loading control U6
and expressed as a fold change compared to a standard sample of LA1-5s. Levels of (D) miR-124 and (E) -375 were normalized to loading control
U6 and expressed as a fold change compared to a SH-SY5Y standard. Each bar represents the mean ± SEM of 3 or more samples.
Samaraweera et al. BMC Cancer 2014, 14:309 Page 5 of 11
http://www.biomedcentral.com/1471-2407/14/30913.0-, 20.0-, and 55.9-fold (P < 0.01), respectively
(Figure 3A).
RA-induced differentiation increases miR-124 expres-
sion 2.0-fold (P < 0.01), whereas BrdU treatment causes a
5.0-fold reduction (P < 0.01) (Figure 3B). Similarly, miR-
375 levels in I cells treated with BrdU decrease ~ 50-fold
(P < 0.01) (Figure 3B). Thus, expression of these miRNAs
characterizes the non-neuronal, non-tumorigenic NB cell
phenotype.
Functional role for miR-335 in S-cell phenotype
To investigate the role for miR-335 in non-neuronal cells,
we down-regulated expression of this miRNA and mea-
sured expression of its predicted target genes and other
genes that regulate cell differentiation. Short-term (4 day)
down-regulation of miR-335 in S-type SH-EP1 cells did
not result in any obvious morphological changes. However,
reduction in miR-335 altered expression of key regulators
of neuronal differentiation, HAND1 and JAG1. HAND1
levels, a proposed target of miR-335 (miRNA.org), in-
creased upon suppression of miR-335 levels (Figure 4A).
HAND1 is critical in differentiation of neural crest cells to
catecholaminergic neurons [14]. Furthermore, neuroblasticcells that do not express miR-335 have the highest levels
of HAND1 and non-neuronal S-cells that have the highest
levels of miR-335 show least amount of HAND1 (Figure 2C
and Figure 4B), suggesting miR-335 may play a critical role
in NB differentiation. Down-regulation of miR-335 also
decreases levels of JAG1, a known ligand for Notch 1
(Figure 4A). Down regulation of Notch signaling is instru-
mental for neuronal differentiation [15]. Accordingly, ex-
pression of JAG1 is highest in non-neuronal-S-cells and
least in neuroblastic cells (Figure 4C). MiR-124, that is
specific for neuroblastic cells, has been shown to decrease
JAG1 expression leading to inactivation of Notch signaling
during miR-124-induced neuronal differentiation [16].
Thus, reciprocal expression of miR-124 and miR-335
seems critical for NB differentiation. In addition, miR-335
is involved in inhibiting metastasis of NB [17], is transcrip-
tionally repressed by N-myc, and has been shown to play a
tumor suppressor role by directly targeting genes like
TGF-β [18]. This finding suggests that miR-335 may also
contribute to the non-tumorigenic properties of S-type
cells. Previous reports accessing miRNAs in primary tu-
mors showed that reduced levels of miR-335 expression






























































































































Figure 4 MiR-335 regulates expression of HAND1 and JAG1- modulators of neuronal differentiation. A. Quantitative changes in miR-335,
HAND1, and JAG1 expression in miR-335 inhibitor-treated SH-EP1 cells. Each bar represents the mean ± SEM of three independent experiments.



















































Figure 3 Drug-induced irreversible differentiation of I-type NB cancer stem cell confirms the association miRNAs with cell phenotype.
A. Fold increases in miR-21, −221 and −335 in BE(2)-C cells differentiated to an S phenotype following a 2 week treatment with 10−5 M BrdU.
B. Changes in miR-124 and −375 expression in BE(2)-C cells treated with RA or BrdU to induce an N or S phenotype, respectively. Each bar
represents the mean ± SEM of 4–6 determinations normalized to untreated controls set =1.0.
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peutic agent.
MiR-124 induces neuronal differentiation of I-type NB
stem cells with concomitant reduction in malignant
potential
Our studies confirm the association of miR-124 to neuro-
blastic cell lines [21,22]. As miR-124 expression is higher
in more neuronal N-cells (Figure 2D) and is elevated
with RA-induced neuronal differentiation (Figure 3B), we
sought to determine whether overexpression of miR-124
by itself is capable of inducing neuronal differentiation of
tumorigenic I-type stem cells. Infection of I-type BE(2)-C
cells with lentivirus coexpressing miR-124 and GFP
induced a neuronal morphology within two weeks of in-
fection. In BE(2)-C/miR-124-infected populations, miR-
124 levels were 4.5-fold (P < 0.001) higher than BE(2)-C
vector-infected populations (Figure 5A). GFP fluorescent









































































Figure 5 miR-124 induces neuronal differentiation in I-type NB cells.
B. Immunofluorescence microscopy of BE(2)-C cells infected with a lentivira
lentiviral vector co-expressing miR-124 and GFP. Photomicrographs were ta
of multiple neuritic processes in C (arrows). D. 3H-NE uptake in BE(2)-C cells
3.7-fold (P < 0.001) with miR-124 lentiviral infection. E. N-myc mRNA levels a
cells compared to control. F. Colony forming efficiencies (CFE) of BE(2)-C ce
CFE is reduced nearly 6-fold following infection (P < 0.001).bodies and markedly increased numbers of elongated
neurites (Figure 5C) compared to control cells (Figure 5B).
Increased 3H-norephinephrine (3H-NE) uptake, an in-
dicator of sympathetic neuron differentiation [23], was
observed with both RA- and miR-124-induced BE(2)-C
cells. RA treatment increased 3H-NE uptake by 1.5-fold
(P < 0.002) and miR-124 infection increased it 3.7-fold
(P < 0.001) (Figure 5D). RA-induced neuronal differen-
tiation is known to reduce N-myc expression [24]. Like-
wise, miR-124-induced neuronal differentiation reduced
N-myc mRNA levels nearly 2-fold (P < 0.008) (Figure 5E).
Thus, increased expression of miR-124 induces neuronal
differentiation in I-type stem cells.
13-cis retinoic acid treatment increases the survival of
patients with high-risk NB [25]. Thus, we hypothesized
that neuronal differentiation following miR-124 over-
expression might also decrease cell tumorigenicity. Col-
ony-forming efficiency (CFE) in soft agar revealed that,





































A. The miR-124 levels in control and miR-124-infected BE(2)-C.
l-vector expressing GFP (control) or (C) BE(2)-C cells infected with
ken two weeks after infection. Note the increase in number and size
is increased 1.5–fold (P < 0.002) following treatment with RA and
re decreased ~2-fold (P < 0.008) in BE(2)-C/miR-124 lentiviral vector
lls stably infected with miR-124 lentiviral vector or control. Note that
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a significant 5.7-fold reduction in malignant potential
(P < 0.001).1 2 3 4 5 6 7 8




















Figure 6 miR-375 expression is regulated by N-myc. A. Representative
(3), LA1-55n (4), KCN-83n (5), SK-N-BE(1)n (6), CB-JMN (7), BE(2)-C (8), SK-N-L
B. Changes in miR-375 levels, compared to U6, in N-myc antisense-transfec
(sense) compared to vector-transfected (vec) controls. C. Chromatin immun
complexes cross-linked with formaldehyde were isolated and sonicated (In
antibodies to N-myc or RNA polymerase II (Pol II) or with goat anti-rabbit s
miR-375 E-box sequence (1), Hook1 (2), and GAPD (3). Note that primers spe
the association of N-myc with those genes.Several other researchers have shown that miR-124 ex-
pression is related to neuronal differentiation [21,22].
Consistent with our findings, Le et al. showed that over9 10 11 12 13
N-myc
Actin









western blot of N-myc protein - SH-SY5Y (1), SMS-LHN (2), BE(2)-M17V
D (9), SK-N-HM (10), SH-EP1 (11), SMS-KCNs (12), and LA1-5s (13).
ted (As) LA1-55n cells and N-myc sense-transfected SH-SY5Y cells
oprecipitation analysis of N-myc regulation of miR-375. DNA-protein
put DNA). Aliquots (1% of input) were immunoprecipitated with
econdary antibody. DNA was amplified by PCR with primers specific to
cific for miR-375 and GAPD E-box sequences gave a band indicating
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outgrowth [26]. Clinically, neuronal differentiation in
NB tumors is associated with reduced malignancy and
tumor regression [25]. Therefore, miR-124 has the po-
tential for use as a therapeutic miRNA in NB.
N-myc regulates expression of miR-375
Neuroblastic cells express both N-myc [3] and miR-375
(Figure 2B and Figure 5A). By contrast, S-cells have
barely detectable levels of this proto-oncogene [3] or
miR-375. miR-375 expression levels in N-myc-expres-
sing cells are ~4-fold higher compared to non-expressing
cells. Moreover, I-type stem cells differentiated to S-cells
have barely-detectable levels of N-myc [3] and miR-375
(Figure 3A). Therefore, expression of miR-375 might be
regulated by N-myc. This oncoprotein regulates gene ex-


















Figure 7 MiR-375 regulates HUD. A. ELAVL4 (HuD) mRNA 3’-UTR comple
of the miR-375 binding site in 3’-UTRs of ELAVL4 mRNA across different spe
inhibitor-treated BE(2)-C cells compared to control oligo-treated cells. Bars repr
western blot of HuD protein levels in miR-375-inhibitor and control oligo-treatethe promoter region of the miR-375 gene contains several
cis-acting elements, including two conserved non-canon-
ical E-box sequences which are essential for optimal ac-
tivity [27]. We measured changes in N-myc protein and
miR-375 expression levels in clones of N-myc amplified
LA1-55n N-cells stably transfected with an antisense con-
struct to N-myc [28]. The >2-fold decrease in N-myc cor-
related with a 4-fold reduction in miR-375 (Figure 6B).
Conversely, N-myc sense transfectants of N-myc non-
amplified SH-SY5Y cells, which have a 1.8-fold increase in
N-myc protein [28], have a 5-fold increase in expression
of miR-375 (Figure 6B).
ChIP experiments confirmed that N-myc binds to one
of two E-box sequences in the promoter region of the
miR-375 gene (Figure 6C). N-myc binding specificity
was confirmed with GAPD as a positive control [which




















ment homology with miR-375 (www.microRNA.org). B. Conservation
cies. C. Relative levels of miR-375 and HuD protein in miR-375
esent the mean ± SD of three independent experiments. D. Representative
d BE(2)-C cells.
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E-boxes). This experiment also shows that RNA Poly-
merase II is associated with the promoter region of miR-
375 in BE(2)-C cells (Figure 6C).HuD is regulated by miR-375
We next screened target prediction sites for miR-375
target genes to identify possible partners involved with
malignancy and differentiation in NB. Of interest, HuD,
a neuronal-specific RNA-binding protein that influences
neuronal differentiation [30], was among the predicted
targets. The HuD 3’-UTR has a 7-mer miR-375 binding
site (Figure 7A), which is highly conserved among spe-
cies (Figure 7B). To determine whether this miRNA is
involved in post-transcriptional regulation of HuD, BE
(2)-C cells were transiently transfected with miR-375 in-
hibitor or negative control: miR-375 levels were reduced
by ~95% (P < 0.05) and HuD protein levels increased
2.9-fold (P < 0.01) in inhibitor-treated cells compared to
control (Figure 7C, D). Thus, miR-375 appears to down
regulate HUD expression. A recent study showed that
down regulation of HuD by miR-375 inhibits neuronal
differentiation [30]. Therefore, in N- and I-type cells,
high miR-375 levels may suppress neuronal differen-
tiation by targeting HUD and thereby maintain the cells
in a less differentiated, more proliferative, state. Suppor-
ting its role as a tumorigenic miRNA in neuroblastoma,
increased expression of miR-375 is associated with pa-
tients with unfavorable outcome and metastatic dis-
semination [17] and miR-375 is one of the ten miRNAs
whose increased expression is associated with advanced
stage neuroblastoma [31].Conclusions
Our study shows that expression of specific miRNAs
defines different NB cell phenotypes and are responsible
for their associated tumorigenic and differentiation pro-
perties. The expression of three miRNAs, miR-21, miR-
221 and miR-335, are exclusive to non-tumorigenic NB
cell phenotype. Evidence suggests miR-335 maintains the
non-neuronal features possibly by blocking neuronal dif-
ferentiation. MiR-124 expression is exclusive to neuro-
blastic cells and overexpression of this miRNA in NB
stem cells induces terminal differentiation with concomi-
tant reduction in their malignant potential, suggesting a
therapeutic potential for this miRNA in treating NB. The
expression of miR-375 is associated with tumorigenic neu-
roblastic cell phenotype and we report that its expression
is regulated by N-myc. MiR-375 downregulates HuD, a
gene involved in neuronal differentiation. The differen-
tiation state of the tumor is highly predictive of survival of
NB patients. Thus, the involvement and association of
these miRNAs in differentiation of NB could be used asprognostic markers and also in development of novel
therapeutic strategies for this enigmatic childhood cancer.
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